Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.

Breast cancer research : BCR - 1 Jan 2006

Munzone Elisabetta, Curigliano Giuseppe, Rocca Andrea, Bonizzi Giuseppina, Renne Giuseppe, Goldhirsch Aron, Nolè Franco

Abstract excerpt

INTRODUCTION: The amounts of estrogen receptor (ER) and progesterone receptor (PgR) in a primary tumor are predictive of the response to endocrine therapies of breast cancer. Several patients with ER-positive primary tumors relapse after adjuvant endocrine therapy with no ER expression in the recurrent tissue; much fewer with a recurrent disease after an ER-negative primary tumor may become endocrine responsive....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Infusions, Intravenous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Paclitaxel

Share to Receptor, ErbB-2

Share to Receptors, Progesterone

Share to Trastuzumab

Share to Vinblastine

Share to Vinorelbine

Source

Open in PubMed Open full text

Identifiers

PMID: 16417653
DOI: 10.1186/bcr1366
PMCID: PMC1413988

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.PMID 16417653Read ↗

Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.Semantic proximity Read ↗

Oestrogen receptor: a stable phenotype in breast cancer.Semantic proximity Read ↗

Estrogen receptors: new perspectives in breast cancer management.Semantic proximity Read ↗

Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer.Semantic proximity Read ↗

Factors predictive of response to hormone therapy in breast cancer.Semantic proximity Read ↗

Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.Semantic proximity Read ↗

Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort studySemantic proximity Read ↗

Intermittent hormonal therapy shows similar outcome than SOC in ER+ breast cancer preclinical modelSemantic proximity Read ↗

Estradiol Regulates Different Genes in Human Breast Tumor Xenografts Compared with the Identical Cells in CultureSemantic proximity Read ↗

Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression*.Semantic proximity Read ↗

Estrogen receptor expression profile of disseminated epithelial tumor cells in bone marrow of breast cancer patients.Semantic proximity Read ↗

Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.